Date: Wednesday, 13 April 2016
Time: 17.30 – 20.00
Address: Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
Registration is now open. Please click here to register. Registration closes one week prior to the meeting.
Professor Ian Churcher, Head, Protein Degradation Discovery Performance Unit, GSK – In Vivo Protein Knockdown by Therapeutic Small Molecule Agents
Dr Jeff Barrett, Director CTTV and Group Leader, Human Genetics, Sanger Institute – Using Human Genetics to Find New Medicines
A scientific forum open to all scientists interested in research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations.
The purpose of Cambridge New Therapeutics Forum (CamNTF) is to promote interactions between scientists at these organisations in order to improve opportunities for biotechnology research and development.
Launched in 2015, CamNTF hosts early-evening meetings open to all scientists interested in research into new therapeutics. These rotate around different organisations located in the Cambridge biotech cluster. Each two-hour session will begin with short scientific presentations and will be followed by networking and snacks (6pm-8pm). Attendance is free but all attendees must register in advance. Places are limited and early registration will be important to avoid disappointment!
Professor Sir Tom Blundell (University of Cambridge, Sir William Dunn Professor of Biochemistry),
Professor Patrick Maxwell (University of Cambridge, Regius Professor of Physic, Director Cambridge University Health Partners),
Professor Michael Wakelam (Babraham Institute, Director),
Professor Ewan Birney (EMBL-EBI, Associate Director),
Dr Mene Pangalos (AstraZeneca, R&D Director),
Professor Ian Wilkinson (University of Cambridge, Professor of Therapeutics; Director of CUHP’s Office for Translational Research).